The Phantom Cure: Susann Cargnino’s $7 Million Medical Device Mirage

The medical testing devices looked convincing enough. Sleek chassis, digital readouts, professional branding—the kind of equipment you’d expect to see in a physician’s office or a wellness clinic. Between 2017 and 2020, Biogenic, Inc. and its network of affiliated companies shipped hundreds of these machines across Michigan and beyond, promising doctors and investors alike that they were on the ground floor of a healthcare revolution. The devices, marketed under names like “Bio-Meridian” and touted as cutting-edge diagnostic tools, supposedly could detect everything from nutritional deficiencies to chronic disease markers through non-invasive testing.

There was just one problem: the doctors who received them performed few, if any, tests.

The machines weren’t worthless—they functioned, technically—but they existed primarily as props in an elaborate stage play. The real business of Biogenic wasn’t healthcare diagnostics. It was selling shares in a company built on the promise of future revenue from medical testing that would never materialize at scale. By the time the Securities and Exchange Commission filed its complaint in the Eastern District of Michigan in October 2021, Susann Ashley Cargnino and her co-conspirators had extracted over $7 million from investors who believed they were funding the next breakthrough in preventative medicine.

On April 29, 2025, a federal judge ordered Cargnino and five others to pay over $17 million in combined monetary relief, marking the final chapter in a fraud that exploited Americans’ endless appetite for wellness innovation and their trust in the medical establishment.

The Cargnino Connection

Susann Ashley Cargnino didn’t fit the stereotype of a medical fraudster. She wasn’t a disgraced physician or a snake oil salesman with a criminal record. Her involvement in the scheme was intertwined with family and business relationships that gave the operation its veneer of legitimacy. Court documents identify her alongside Zachari Alan Cargnino—the shared surname suggesting a familial bond that prosecutors would later argue created a web of control across multiple corporate entities designed to obscure the fraud’s true nature.

The Michigan-based operation revolved around not one but six separate companies, all interconnected through overlapping ownership and management. Biogenic, Inc. sat at the center, but the network included related entities that allowed the conspirators to move money, create false paper trails, and present investors with what appeared to be a diversified, growing healthcare business. Susann Cargnino’s exact role varied across these companies, but her presence in the corporate structure was consistent—a name on formation documents, a signature on bank accounts, a voice on investor calls.

What made the scheme particularly insidious was its exploitation of the alternative medicine boom. By 2017, Americans were spending tens of billions annually on wellness products and services outside traditional medicine—supplements, functional medicine, biometric testing, personalized nutrition plans. The market was ripe with optimism and loose with scrutiny. Investors, many of them individuals rather than institutions, were primed to believe that the next Theranos or 23andMe could emerge from a Michigan office park.

The Cargninos and their partners—Gary Youssef and Julie Ann Youssef among them—understood this landscape. They spoke the language of disruption, prevention, and patient empowerment. They presented Biogenic not as a medical device manufacturer but as a technology company positioned at the intersection of healthcare and data analytics, a story investors had been trained to find irresistible.

The Architecture of Illusion

The fraud’s mechanics were sophisticated in their simplicity. Rather than invent a completely fictional product, the conspirators used real medical devices—Bio-Meridian systems and similar equipment that had legitimate, if limited, applications in certain holistic medicine practices. These weren’t FDA-approved diagnostic tools for mainstream medical use, but they existed, they had manufacturers, and they generated real invoices and shipping records.

The deception lay in what Biogenic told investors about how these devices would be used and, crucially, what revenue they would generate.

According to the SEC’s complaint, filed in October 2021 in the Eastern District of Michigan (Case No. 5:21-cv-12236), the defendants solicited investments by representing that Biogenic had developed a profitable business model built around placing testing equipment with physicians who would then perform diagnostic tests on patients. Each test, investors were told, would generate fees that would flow back through the network of Biogenic entities, creating a steady revenue stream that would justify the company’s rising valuation and provide returns to shareholders.

The investment materials painted a picture of explosive growth. Projections showed hundreds of devices deployed, thousands of tests performed monthly, and revenue curves that bent sharply upward. The defendants allegedly provided investors with financial statements and business updates that reinforced this narrative—charts showing device placements, graphs depicting test volume, and forecasts that promised profitability was just around the corner.

But the doctors weren’t using the machines.

Court documents reveal the devastating truth: physicians who received Biogenic’s testing equipment performed few, if any, tests. Some devices sat in boxes, never uncrated. Others were set up in offices but rarely powered on. The promised flood of test revenue never materialized because the business model—placing equipment with physicians who would integrate complex, non-traditional diagnostic tools into their practices—was fundamentally flawed.

Traditional medicine operates on evidence, standards of care, insurance reimbursement, and regulatory approval. Biogenic’s devices existed in the alternative medicine space, where adoption depended on individual physician interest, patient willingness to pay out of pocket, and demonstrated clinical value. The defendants had apparently never done the hard work of proving any of these elements could scale.

Instead of revenue from medical testing, Biogenic’s cash flow came almost entirely from new investor money. This is the classic definition of a Ponzi-adjacent scheme: using fresh capital to create the illusion of business success while the underlying operation generates little to no legitimate income.

The Money Trail

Between approximately 2017 and 2020, the defendants raised over $7 million from investors, according to SEC allegations. That money didn’t go toward building a sustainable medical testing business. Instead, court filings suggest it was cycled through the network of six affiliated companies, obscuring its true uses.

Some funds purchased the medical devices themselves—necessary to maintain the facade that Biogenic was a real operating company. The defendants needed actual equipment to show investors, to photograph for marketing materials, and to ship to physician offices. These purchases created legitimate-looking expenses and vendor relationships that made Biogenic appear operational.

But a significant portion of investor capital appears to have been diverted to the defendants personally or used to pay earlier investors, creating the illusion of returns. The multi-company structure was essential to this misdirection. Money could be transferred between entities as purported loans, management fees, or service payments. Financial statements for any single company might show expenses that seemed reasonable—until investigators traced where those payments actually went.

The SEC’s enforcement action charged violations of multiple securities laws, including Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5, the federal statutes prohibiting fraudulent conduct in connection with securities sales. The complaint also alleged violations of Section 17(a) of the Securities Act of 1933, which bars fraud in the offer or sale of securities, and Section 5 of the Securities Act, which requires registration of securities offerings or qualification for an exemption.

This last charge is particularly significant. The defendants weren’t just accused of lying about Biogenic’s business—they were accused of selling unregistered securities. In raising millions from investors in exchange for shares or membership interests in their companies, they triggered federal registration requirements designed to ensure investors receive accurate information. By allegedly failing to register their offerings and by not qualifying for any exemption, the defendants denied investors the basic protections that securities laws provide.

The paper trail extended beyond bank accounts and corporate filings. The SEC complaint references investor communications—emails, presentations, and financial reports—that allegedly contained materially false and misleading statements. Prosecutors would later argue that these weren’t innocent mistakes or overly optimistic projections. They were, according to the complaint, intentional misrepresentations designed to induce investment in a business the defendants knew wasn’t generating the revenue they claimed.

The Web of Entities

Understanding the fraud requires mapping the corporate maze. Six Michigan companies formed the operational structure, each serving a distinct purpose in the scheme:

Biogenic, Inc. functioned as the flagship, the name attached to investor presentations and marketing materials. It was the brand, the entity investors believed they were funding.

The five other companies remain identified in court documents but operated in supporting roles—some holding assets, others managing contracts with physicians, still others serving as vehicles for moving money between related parties. Susann Cargnino’s name appeared across these entities in varying capacities, as did those of Zachari Cargnino, Gary Youssef, and Julie Ann Youssef.

This corporate complexity served several functions. It made due diligence harder for investors, who couldn’t easily track cash flows across multiple entities. It created legal ambiguity about liability—if one company was sued, assets might be held in another. And it provided a mechanism for accounting gymnastics, allowing revenue, expenses, and profits to be characterized differently depending on which entity’s books were being examined.

The SEC’s investigation, which culminated in the 2021 complaint, required forensic accountants to unwind years of inter-company transactions. Investigators traced investor funds from initial deposits through dozens of transfers, reconstructing what money went where and for what purpose. This kind of financial archaeology is standard in complex fraud cases, but it’s time-consuming and resource-intensive—one reason why such schemes can persist for years before regulatory action.

The Unraveling

The SEC complaint filed in October 2021 doesn’t detail the specific trigger that initiated the investigation. Such cases typically begin one of several ways: investor complaints, whistleblower tips, regulatory examinations, or suspicious activity reports from financial institutions.

Given the nature of the scheme, the most likely scenario involves investors who stopped receiving the returns they’d been promised. As the flow of new investor capital slowed—perhaps due to the economic disruptions of 2020 or simply market saturation—the defendants would have struggled to maintain the appearance of profitability. Earlier investors might have requested redemptions or demanded detailed financial documentation. When answers weren’t forthcoming or didn’t make sense, complaints to regulators would have followed.

Federal securities investigations move methodically. The SEC has subpoena power to compel production of documents and testimony. Investigators likely obtained bank records, corporate filings, emails, and investor communications. They would have interviewed victims—the investors who lost money—as well as third parties like the physicians who received but didn’t use the testing equipment. These doctors, likely unaware they were part of a fraud, could testify that the devices sat unused, undermining the defendants’ claims of revenue from testing.

By the time the SEC filed its complaint in the Eastern District of Michigan, the case was extensively documented. The 2021 complaint laid out the alleged violations with specificity: who said what to whom, when money changed hands, which statements were false, and how investors were harmed. Federal complaints in securities fraud cases aren’t speculative—they’re built on documentary evidence and testimony sufficient to persuade a judge that the case should proceed.

The filing of the complaint itself typically triggers immediate consequences. Assets may be frozen to preserve them for eventual restitution to victims. Defendants often face pressure to settle quickly rather than face trial. And their ability to conduct business—particularly in regulated industries like securities or healthcare—evaporates as word of the charges spreads.

The Legal Reckoning

The case proceeded through the federal court system over nearly four years. While public records don’t detail every hearing, motion, and negotiation, the trajectory from complaint to final judgment suggests either a settlement or a ruling after trial.

The final judgment, entered on April 29, 2025, ordered over $17 million in monetary relief against the six companies and four individual defendants, including Susann Cargnino. This figure significantly exceeded the approximately $7 million that investors lost, reflecting the way securities penalties are calculated.

In SEC enforcement actions, monetary relief typically includes three components: disgorgement, prejudgment interest, and civil penalties. Disgorgement aims to strip defendants of ill-gotten gains—essentially clawing back the money they obtained through fraud. Prejudgment interest compensates for the time value of money victims lost. And civil penalties serve as punishment and deterrence, with amounts determined by statutory formulas based on the violation’s severity.

Susann Cargnino’s individual portion of this judgment was $8.7 million, according to the SEC’s litigation release. Whether this represents joint and several liability with co-defendants or an individual calculation based on her specific role and benefit isn’t specified in the summary documents, but the amount suggests the court found her deeply involved in the scheme’s operation and significantly enriched by it.

The charges against Cargnino—violations of Section 10(b) and Rule 10b-5, Section 17(a), and Section 5—carry both monetary and equitable consequences. Beyond the $8.7 million judgment, defendants in such cases typically face injunctions barring them from future violations, effectively prohibiting them from working in securities industries or soliciting investments. These injunctions follow defendants for life, making it nearly impossible to raise capital or serve as an officer or director of a public company.

Criminal charges weren’t mentioned in the SEC’s civil enforcement action, but that doesn’t mean criminal prosecution is impossible. The Department of Justice often pursues parallel criminal cases in major securities frauds, particularly when losses exceed several million dollars and the fraud involved intentional deception rather than negligent misrepresentation. Criminal securities fraud carries potential prison time—up to 20 years for wire fraud, for instance—in addition to fines and restitution orders.

The Eastern District of Michigan, where the case was filed, has seen its share of fraud prosecutions. Federal prosecutors there work closely with SEC investigators, often building criminal cases on the same evidence developed for civil enforcement. Whether Susann Cargnino or her co-defendants faced criminal jeopardy remains unclear from available records, but the size of the fraud and the apparent intentionality described in the SEC complaint would certainly justify such charges.

The Victims’ Calculus

Behind the dollar figures and legal violations were real people who lost real money. Over $7 million divided among investors means individual losses likely ranged from tens of thousands to hundreds of thousands of dollars, depending on how many investors were involved and how the capital was distributed.

SEC complaints typically don’t name victims, but the profile of investors in a scheme like Biogenic’s can be inferred. These weren’t institutional investors or venture capital firms—sophisticated actors with due diligence teams and diversified portfolios. They were likely individuals: entrepreneurs who believed in the healthcare technology story, retirees looking for better returns than bonds or CDs offered, professionals in medical or wellness fields who understood the industry narrative and found it credible.

Some may have been friends or family of the defendants, the first circle of investors in many frauds. Others might have been members of investment clubs, church groups, or professional networks where trusted members recommend opportunities to one another. This social dimension is crucial to understanding how frauds spread and persist. When someone you know and trust—someone who seems successful and connected—offers you an investment opportunity, skepticism gets harder to maintain.

The investors in Biogenic likely believed they were funding innovation. They saw themselves as backers of a healthcare startup positioned to capitalize on the trend toward preventative and personalized medicine. The defendants’ pitch probably emphasized the inadequacy of traditional medicine, the growing consumer demand for alternative diagnostics, and the massive market opportunity in wellness.

And on paper, the investment seemed to perform—at least initially. Early investors may have received statements showing their holdings appreciating in value. Some might have been paid “returns,” distributions that were actually just their own capital or money from later investors being recycled. These early positive signals create powerful psychological reinforcement, making investors more likely to invest additional funds and to recruit others.

When the scheme collapsed, these investors faced not just financial loss but psychological trauma. Fraud victims often report feelings of shame, self-blame, and betrayal. They question their own judgment. They struggle to trust again. The monetary judgment against the defendants, while legally significant, offers little practical comfort—most fraud defendants don’t have $17 million in recoverable assets. Judgments are often uncollectible, leaving victims with legal vindication but empty pockets.

The Medical Device Mirage

The choice of medical devices as the fraud’s vehicle is worth examining. Unlike purely financial frauds—fake hedge funds or phantom real estate deals—a medical device scheme has physical components. There are actual machines, actual physicians, actual office visits where tests theoretically could be performed.

This tangibility makes the fraud more convincing. Investors could see and touch the devices. They could visit physician offices where equipment was installed. The defendants could produce invoices from device manufacturers, shipping receipts, and contracts with medical practices. All of this created a paper trail and physical evidence that suggested a real business.

But the medical field also provided cover for why revenue might be slow to materialize. The defendants could blame regulatory hurdles, insurance reimbursement challenges, physician adoption curves, and patient education needs—all legitimate obstacles in healthcare innovation. Investors familiar with the long timelines and complex barriers in medical technology might have been more patient than they would be with a simpler business model.

The specific devices Biogenic promoted—Bio-Meridian and similar systems—occupy a contested space in healthcare. Based on principles from alternative medicine, including acupuncture meridian theory and electrodermal screening, these devices are used by some holistic practitioners but aren’t recognized by mainstream medicine or approved by the FDA for diagnosing medical conditions. This regulatory ambiguity gave the defendants room to operate outside traditional medical device pathways while still claiming legitimacy in the wellness space.

The problem, as investigators discovered, was that even within the alternative medicine community, demand for these specific testing services was insufficient to support the business model Biogenic claimed to have. The defendants needed hundreds of physicians performing thousands of tests monthly to generate the revenue they promised investors. Instead, they had a handful of devices gathering dust.

This gap between promise and reality is the core of the fraud. Had the defendants been honest about their business’s actual state—limited device adoption, minimal testing volume, ongoing losses—they could not have raised $7 million. The fraud was necessary because the business model didn’t work.

The Corporate Shell Game

The use of six separate Michigan companies reveals sophisticated fraud architecture. Each entity served a purpose in the overall scheme while providing legal and financial separation that made the fraud harder to detect and prosecute.

One company might have held the contracts with physicians. Another owned the medical devices. A third managed investor relations. A fourth handled marketing. A fifth and sixth might have been vehicles for moving money or holding real estate and other assets the defendants wanted to protect from eventual creditors.

This structure also creates tax complexity. Each entity files separate returns, potentially allowing defendants to characterize income and expenses in ways that minimize tax liability. Profits in one entity might be offset by paper losses in another. Management fees and licensing agreements between related companies can move money while creating deductible expenses.

For investigators, this corporate maze required assembling a complete picture from fragmented records. The SEC had to obtain documents from all six companies, trace relationships between them, identify beneficial ownership, and reconstruct consolidated financial statements showing what the overall enterprise actually earned and spent.

Susann Cargnino’s involvement across these entities suggests she wasn’t a peripheral figure. In complex corporate frauds, the most culpable defendants are often those who sign documents, authorize transfers, and communicate with investors. Her $8.7 million individual judgment—a substantial portion of the $17 million total—indicates the court found her role central to the scheme’s operation.

The co-defendants—Zachari Cargnino, Gary Youssef, and Julie Ann Youssef—similarly appear throughout the corporate structure. The Youssef surname appearing twice, like the Cargnino surname, suggests family relationships that facilitated trust and coordination among conspirators. Fraud is often a family business, with spouses, siblings, and parents recruited into schemes that require multiple participants to execute.

April 2025: The Final Accounting

The final judgment entered on April 29, 2025, represented the culmination of an enforcement action that began with the SEC’s complaint in October 2021. Nearly four years from complaint to final judgment is typical for complex securities cases, reflecting the time required for discovery, motion practice, and either trial or negotiated settlement.

The monetary relief total—over $17 million against six companies and four individuals—sends a clear message about the scheme’s severity. Federal judges in securities cases have discretion in setting civil penalties, guided by statutory frameworks that consider factors including the violation’s egredeousness, the defendants’ culpability, the harm to investors, and the need for deterrence.

That the judgment exceeds the approximately $7 million in investor losses reflects these additional considerations. The defendants didn’t just take money—they lied to investors, created false documents, operated an unregistered securities offering, and violated antifraud provisions that are foundational to capital markets integrity. Each aggravating factor justifies higher penalties.

For Susann Cargnino, the $8.7 million judgment represents a financial devastation from which recovery is unlikely. Even if the judgment is partially uncollectible—as is often the case when defendants have already spent or hidden assets—the legal liability follows her permanently. It appears on credit reports, survives bankruptcy in many cases, and can be enforced through wage garnishment, property liens, and asset seizures for decades.

Beyond money, the reputational consequences are profound. Her name is now permanently associated with federal securities fraud. A Google search returns SEC enforcement actions, court documents, and news coverage of the scheme. Professional opportunities in finance, healthcare, and most licensed industries evaporate. Social relationships strain under the weight of disgrace.

Whether Cargnino accepted responsibility or continued to maintain innocence isn’t documented in the available records. Defendants in such cases often claim they were misled by others, that they didn’t understand the legal requirements, or that they genuinely believed the business would succeed. These explanations rarely satisfy judges or prosecutors when the evidence shows sustained deception and personal enrichment.

The Pattern and the Warning

The Biogenic fraud fits a pattern seen across securities enforcement: sophisticated actors exploiting investor optimism in high-promise sectors. Healthcare technology, like cryptocurrency, renewable energy, and artificial intelligence, attracts investment because the potential returns seem unlimited. Stories of early investors in companies that became household names create powerful FOMO—fear of missing out—that fraudsters exploit.

The medical device angle added credibility. Unlike a completely abstract financial instrument, Biogenic had physical products and real contracts with physicians. This tangibility lowered investor skepticism. The multi-company structure created apparent complexity and sophistication, suggesting a mature organization rather than a startup fraud.

But the warning signs were there for those who knew what to look for. Unregistered securities offerings should always raise questions—why isn’t this investment going through traditional channels? Financial projections that show hockey-stick growth without clear explanation of how that growth will be achieved are red flags. And any investment where access seems limited—you have to know someone, there’s urgency to invest now—should trigger caution.

The fundamental lesson from the Biogenic case is the importance of independent verification. Investors should demand audited financial statements from reputable accounting firms. They should verify claims about business operations—in this case, calling physicians’ offices to ask about their experience with the testing equipment. They should consult with lawyers and accountants before committing significant capital.

None of these steps guarantee protection against fraud, but they create hurdles that make schemes harder to execute. The Biogenic defendants succeeded because investors took their claims at face value, trusted the apparent sophistication of the operation, and failed to independently verify that the testing revenue they were promised was actually being generated.

Aftermath and Reckoning

The final judgment closes the SEC’s civil case but doesn’t necessarily end the story. Victims may pursue their own civil litigation seeking additional damages. State securities regulators in Michigan may bring parallel enforcement actions. And federal prosecutors may still be evaluating whether criminal charges are warranted.

For the victims, the judgment offers validation—an official acknowledgment that they were defrauded—but likely little financial recovery. The SEC doesn’t operate a compensation fund for securities fraud victims. Any distributions would come from assets seized from the defendants, and in cases like this, defendants typically have spent or hidden most of the money by the time judgments are entered.

The four individuals and six companies named in the enforcement action face operational extinction. The companies, if they still exist on paper, are almost certainly defunct. Their business reputations are destroyed, their ability to operate eliminated by the injunctions and judgments against them. The individual defendants face not just financial liability but the permanent stain of federal fraud findings.

For Susann Cargnino specifically, the judgment represents a turning point from which there is no return to her previous life. Whether she attempts to rebuild in some unrelated field, faces additional criminal prosecution, or disappears into obscurity will depend on factors not visible in the public record. But her role in the $7 million medical device fraud will define her public identity from this point forward.

The physician offices that received but never used the testing equipment represent another category of victims. While not financially harmed—they didn’t pay for the devices—they may face awkward questions about why they agreed to participate in a program they didn’t actually use. Some may have had genuine interest in the technology but found it impractical to integrate into their practices. Others may have been misled about what participation would require.

The broader healthcare and investment communities will likely take note of the case as another cautionary tale about due diligence and the dangers of early-stage medical device investments. But memory is short, and similar schemes will inevitably emerge, dressed in new technology and promising different breakthroughs.

The Silence of the Devices

In the end, what makes the Biogenic fraud particularly poignant is its foundation on machines that did nothing. Hundreds of medical testing devices, shipped to physician offices across Michigan and beyond, sat unused. They weren’t broken. They weren’t fake. They simply existed, inert physical evidence of a business model that never worked.

Those silent devices—gathering dust in storage rooms, returned to warehouses, or eventually discarded—represent the material reality of a $7 million lie. Every investor dollar supposedly funded a vision of preventative healthcare, of early detection, of technology empowering physicians and patients. Instead, it funded the lifestyles and expenses of four individuals who understood that the promise itself was the product.

The SEC’s final judgment, announced on April 29, 2025, ordering over $17 million in monetary relief, closes the regulatory chapter of the Biogenic story. But the human consequences—the life savings lost, the trust betrayed, the professional reputations destroyed—will extend far beyond any court order.

Somewhere in Michigan, some of those medical devices may still sit in their original packaging, never unboxed, never powered on, never used for a single diagnostic test. They are monuments to optimism exploited, to complexity deployed as camouflage, and to the eternal truth that in fraud, the most convincing lies are built on fragments of reality.

Susann Ashley Cargnino and her co-conspirators understood that truth well. They just forgot that fragments eventually reveal themselves for what they are—pieces of something that was never whole.